文献速递临床试验与 GCP基础与转化研究

抗寨卡病毒DNA疫苗的安全性与免疫原性

Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.
PubMed 文献 · N Engl J Med · 2021-01-01

这项1期开放标签临床试验评估了编码寨卡病毒前膜蛋白和包膜蛋白的合成共识DNA疫苗(GLS-5700)的安全性和免疫原性。两组各20名参与者分别接受1 mg或2 mg疫苗皮内注射,每次注射后电穿孔,于基线、4周和12周接种。结果显示疫苗可诱导体液免疫应答,且初步安全性可接受。

要点

  • 1 mg和2 mg GLS-5700均可诱导结合抗体,几何平均滴度分别为1642和2871。
  • 62%样本在Vero细胞试验中产生中和抗体。
  • 接种后血清可保护92%的IFNAR敲除小鼠免受致死性寨卡病毒攻击。

核心结论

  • 在1期开放标签临床试验中,DNA疫苗GLS-5700可诱导体液免疫应答。
  • 需进一步研究以更好评估该疫苗的安全性和有效性。

研究设计与样本

  • 1期开放标签临床试验,两组各20名参与者。
  • 参与者分别接受1 mg或2 mg GLS-5700皮内注射,每次注射后电穿孔,于基线、4周和12周接种。

主要发现

  • 14周中期分析时,未报告严重不良事件。
  • 约50%的参与者出现接种部位局部反应,如注射部位疼痛、发红、肿胀和瘙痒。
  • 第三剂后,所有参与者的酶联免疫吸附试验均可检测到结合抗体,1 mg和2 mg组的几何平均滴度分别为1642和2871。
  • 62%的样本在Vero细胞试验中产生中和抗体。
  • 在神经元细胞试验中,70%的血清样本对寨卡病毒感染有90%抑制,95%的样本有50%抑制。

关键数值与推荐

  • 结合抗体几何平均滴度:1 mg组1642,2 mg组2871。
  • 中和抗体在Vero细胞试验中阳性率为62%。
  • 神经元细胞试验中,70%样本有90%抑制,95%样本有50%抑制。
  • 小鼠保护率:接种后血清组92%(103/112),基线血清组0%。

临床怎么用

  • 该1期试验提示GLS-5700 DNA疫苗具有可接受的初步安全性和免疫原性,但尚未批准用于临床。
  • 需进一步研究以评估疫苗在更大规模人群中的安全性和保护效力。

局限性

  • 为1期开放标签临床试验,样本量小。
  • 未评估疫苗对寨卡病毒感染的保护效力。
  • 需进一步研究以更好评估安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although Zika virus (ZIKV) infection is typically self-limiting, other associated complications such as congenital birth defects and the Guillain-Barré syndrome are well described. There are no approved vaccines against ZIKV infection. METHODS: In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each. The participants received either 1 mg or 2 mg of vaccine intradermally, with each injection followed by electroporation (the use of a pulsed electric field to introduce the DNA sequence into cells) at baseline, 4 weeks, and 12 weeks. RESULTS: The median age of the participants was 38 years, and 60% were women; 78% were White and 22% Black; in addition, 30% were Hispanic. At the interim analysis at 14 weeks (i.e., after the third dose of vaccine), no serious adverse events were reported. Local reactions at the vaccination site (e.g., injection-site pain, redness, swelling, and itching) occurred in approximately 50% of the participants. After the third dose of vaccine, binding antibodies (as measured on enzyme-linked immunosorbent assay) were detected in all the participants, with geometric mean titers of 1642 and 2871 in recipients of 1 mg and 2 mg of vaccine, respectively. Neutralizing antibodies developed in 62% of the samples on Vero-cell assay. On neuronal-cell assay, there was 90% inhibition of ZIKV infection in 70% of the serum samples and 50% inhibition in 95% of the samples. The intraperitoneal injection of postvaccination serum protected 103 of 112 IFNAR knockout mice (bred with deletion of genes encoding interferon-α and interferon-β receptors) (92%) that were challenged with a lethal dose of ZIKV-PR209 strain; none of the mice receiving baseline serum survived the challenge. Survival was independent of the neutralization titer. CONCLUSIONS: In this phase 1, open-label clinical trial, a DNA vaccine elicited anti-ZIKV immune responses. Further studies are needed to better evaluate the safety and efficacy of the vaccine. (Funded by GeneOne Life Science and others; ZIKA-001 ClinicalTrials.gov number, NCT02809443.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Tebas P, Roberts CC, Muthumani K, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine. N Engl J Med. 2021. PMID: 34525286. doi:10.1056/NEJMoa1708120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。